Saving changes...



The biology behind radiotherapy for cancer: Past, present and future

The biology behind radiotherapy for cancer: Past, present and future

The biology behind radiotherapy for cancer: Past, present and future

Veterinary Cancer Society
Veterinary Cancer Society
on behalf of Missouri Veterinary Medical Association


$25.00 $ 25.00 $ 25.00

25.00 $ 25.00 25.00 25.00
Normal Price: FREE $25.00


Launch date: 22 Dec 2016
Expiry Date:

Last updated: 30 Aug 2021

Reference: 167568

TIming: null

Maximum Attendees:

Places Left: 0

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

You have null days left.


Radiation therapy (RT) for cancer has been around for a long time and has evolved as a treatment along with the development of new technologies for radiation delivery. The biological basis for conventional delivery of radiation in 1.8-2.0Gy daily dose fractions 5 times per week at a moderate dose rate was derived empirically. However, it was given credence by elucidation of the 4Rs of radiobiology related to the possible advantages of dose fractionation. The recent advent of IMRT, IGRT, SRS, SRT, SBRT, Cyberknife, Gammaknife, Tomotherapy, RapidArc, HDR brachytherapy, protons, etc, has however encouraged or forced the use of smaller margins, inhomogeneous fields, adaptive radiotherapy, dose painting, and of larger dose fractions with considerable variation in delivery time and dose rate. The biological consequences of many of these changes are essentially unknown, but the way RT is being delivered is changing rapidly. At the same time, RT is seen as being much more than a cytotoxic agent. Of considerable interest is that it can act as an immunological adjuvant. As a result it is being explored in combination with various immunotherapies, in particular immune checkpoint inhibitors. This lecture will deal evaluate some of the constraints on the use of RT in the current era and will discuss where RT may be going in future efforts to improve radiotherapeutic benefit.


Learning Objectives:
• Realize that physics and computing have had a major impact on the field of radiation oncology
• Become aware of the potential of new ways of delivering radiation for cancer therapy
• Become aware of the limitations of new radiation delivery systems for cancer therapy
Veterinary Cancer Society

Author Information Play Video Bio

Veterinary Cancer Society
on behalf of Missouri Veterinary Medical Association

Dr. William McBride - Professor, Radiation Oncology, Assistant Vice-Chancellor for Research, University of California, Los Angeles (UCLA): Dr. McBride was recruited to UCLA as a Professor of Radiation Oncology in 1984. He had previously been a Senior Lecturer in the Department of Bacteriology at the University of Edinburgh Medical School in Scotland (1982-84) and a Project Investigator
in the Department of Radiotherapy and Experimental Radiotherapy at the University of Texas, MD Anderson Hospital and Tumor Institute. In 1987, he received his DSc from the University of Edinburgh. He is currently an Assistant Vice Chancellor for Research and recently completed his 21-year term as the Director of the UCLA Department of Radiation Oncology’s Division of Molecular and Cellular Oncology in 2014. Dr. McBride is an expert in normal tissue and cancer radiobiology with an interest in tumor immunology. He has published extensively in this field, has been successful in receiving many grants in these areas, and is the co-leader of the UCLA Center for Medical Countermeasures Against Radiation (CMCR), a NIAID supported program focused on radiation mitigation research. Additionally, Dr. McBride has been an instructor and organizer for the Biomedical Physics Graduate Program over the past 26 years and has supervised over 60 students on various research projects.

Ashley French DVM is a 2012 graduate of the University of Missouri College of Veterinary Medicine. She is a small animal practitioner at Weathered Rock Veterinary Clinic in Jefferson City MO. She is the assistant director of the Volunteer Veterinary Corps.

Charles E. Massengill, DVM, is presently with CRM Veterinary Consulting. He graduated from Kansas State University in 1979. He presently serves as director of the Missouri Volunteer Veterinary Corps. He is also a member of the Emergency Management & Public Health Committee and Missouri Stocker Feeder Quality Assurance Program.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Missouri Veterinary Medical Association
  • 1.00 Hours -
    Exam Attempts: 3
    Exam Pass Rate: 60

Faculty and Disclosures

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:


User Reviews (0)

Go Back


Saving changes...